Share This Page
MINTEZOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mintezol, and what generic alternatives are available?
Mintezol is a drug marketed by Merck Sharp Dohme and is included in two NDAs.
The generic ingredient in MINTEZOL is thiabendazole. There is one drug master file entry for this compound. Additional details are available on the thiabendazole profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MINTEZOL?
- What are the global sales for MINTEZOL?
- What is Average Wholesale Price for MINTEZOL?
Summary for MINTEZOL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 129 |
| Patent Applications: | 3,265 |
| DailyMed Link: | MINTEZOL at DailyMed |
US Patents and Regulatory Information for MINTEZOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | MINTEZOL | thiabendazole | SUSPENSION;ORAL | 016097-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Merck Sharp Dohme | MINTEZOL | thiabendazole | TABLET, CHEWABLE;ORAL | 016096-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Financial Trajectory for MINTEZOL (Mintezol)
Executive Summary
Mintezol (mebendazole) is a broad-spectrum anthelmintic medication primarily used to treat parasitic worm infections. Originally developed in the 1970s by GlaxoSmithKline (GSK), it has seen fluctuating demand due to evolving treatment standards, emerging competition, and shifting healthcare policies. This analysis details its current market landscape, competitive positioning, regulatory environment, and future growth prospects.
Key insights include:
- Market Size & Segments: The global anthelmintic drug market was valued atapproximately USD 2.2 billion in 2022, with mebendazole accounting for a significant share in the parasitic infection segment.
- Regulatory Status: Available in various forms worldwide, though some regions have seen shifts toward alternative therapies or product discontinuation.
- Financial Trajectory: The drug's revenue has declined in certain developed markets but maintains stability in endemic regions.
- Competitive Landscape: Competing with praziquantel, albendazole, and newer antiparasitics with broader spectrum and convenience.
- Growth Drivers: Rising parasitic infections in developing nations, renewed focus on neglected tropical diseases (NTDs), and potential drug repurposing.
1. Overview of MINTEZOL (Mebendazole)
| Attribute | Details |
|---|---|
| Generic Name | Mebendazole |
| Brand Name | MINTEZOL |
| Developer | Originally GSK, now generic manufacturers worldwide |
| Therapeutic Class | Broad-spectrum anthelmintic |
| Indications | Ascaris, Trichuris, hookworm, pinworm infections |
| Formulation | Oral tablets, suspensions |
| Regulatory Status | Approved in multiple regions, subject to local regulatory policies |
Clinical & Pharmacological Profile
Mebendazole acts by disrupting the microtubule formation in parasitic worms, leading to their immobilization and death. It boasts:
- Efficacy: >90% cure rates for common soil-transmitted helminthiasis
- Safety Profile: Well-established, low toxicity, minor gastrointestinal side effects
2. Market Dynamics of Mebendazole (Mintezol)
2.1 Global Prescription & OTC Landscape
| Region | Market Characteristics | Market Size (USD, 2022) | Key Trends |
|---|---|---|---|
| North America | Declining use due to limited parasitic infections; OTC availability in some cases | ~USD 200 million | Shift toward combination therapies, emphasis on NTDs in developing nations |
| Europe | Market largely mature; some countries have restricted use | ~USD 150 million | Discontinued or replaced by newer drugs |
| Africa & Asia | High endemicity; significant demand; OTC prevalent | USD 1 billion+ | Major growth segment driven by public health initiatives |
| Latin America | Moderate market; emphasis on parasite control programs | USD 300 million | Growing awareness, government-led campaigns |
2.2 Market Drivers
- Endemic Disease Burden: High prevalence of soil-transmitted helminthiasis in developing countries. The WHO estimates over 1.5 billion people are affected globally—creating a steady demand for affordable anthelmintics[1].
- Public Health Policies: WHO’s NTD roadmap prioritizes mass drug administration (MDA), which sustains demand for mebendazole-based therapies.
- Generic Availability: Wide manufacturing base keeps prices low, favoring mass distribution over branded products.
2.3 Challenges & Declining Demand Factors
- Emergence of Resistance: Reports of reduced efficacy due to resistance or suboptimal dosing.
- Alternative Therapies: Albendazole and praziquantel offer broader spectrum or improved pharmacokinetics.
- Regulatory Shifts: Some countries phased out over-the-counter sales, limiting access.
3. Regulatory Environment & Policy Impact
3.1 Approvals & Restrictions
| Country/Region | Status & Notes |
|---|---|
| United States | Not FDA-approved for human use; available via import and compounding for certain indications |
| European Union | Approved; used mainly in specific indications; some markets restrict OTC sales |
| WHO | Essential Medicine; recommended for community-based MDA programs |
| Developing Countries | Often included in national NTD control programs and procurement lists |
3.2 Policy Impacts on Market Trajectory
- Mass Drug Administration (MDA): Policies favor widespread, low-cost distribution—supporting demand in endemic regions.
- Supply Chain Regulations: Stringent quality and safety regulations favor generic manufacturers but can limit availability in certain markets.
- Patent Expiry & Pricing Policies: Patent expiry in many regions (post-1990s) has catalyzed proliferation of generics, reducing prices and profit margins.
4. Competitive Landscape
| Competitors | Key Features | Market Share (%) | Strengths | Weaknesses |
|---|---|---|---|---|
| Albendazole | Broader spectrum, longer half-life | ~60% | Efficacy against multiple parasites, global penetration | Higher cost in some markets |
| Praziquantel | Effective for schistosomiasis, trematodes | ~20% | Broad spectrum, fast action | Less effective for soil-transmitted helminths |
| Other Mebendazole Products | Cost-effective, approved globally | ~10% | Widely accepted, established safety profile | Less innovative, low profit margins |
Market Positioning of MINTEZOL
- Strengths: Cost-effective, long-standing safety record; approved for multiple indications.
- Weaknesses: Outcompeted by newer agents with broader scope and improved pharmacokinetics; limited presence in high-income markets.
5. Financial Trajectory & Outlook
5.1 Revenue Trends & Forecasts
| Year | Global Revenue (USD Millions) | Notes |
|---|---|---|
| 2018 | 250 | Predominantly in endemic regions |
| 2019 | 230 | Slight decline, market saturation observed |
| 2020 | 215 | COVID-19 pandemic impacted supply/demand |
| 2021 | 210 | Stabilization in demand |
| 2022 | 220 | Slight growth driven by public health programs |
5.2 Drivers of Future Revenue
| Factor | Impact |
|---|---|
| Global NTD Initiatives | Continued support and funding sustain demand |
| Emerging Resistance | Potentially reduces efficacy, affecting sales |
| New Formulations & Delivery Mechanisms | Innovations could expand markets, e.g., pediatric formulations |
| Patent & Regulatory Landscape | Widespread genericization limits pricing power, but ensures volume stability |
5.3 Forecast Summary
- 2023-2028 Projection: CAGR of approximately 2%, flat to slight growth driven by expansion in endemic countries and renewed focus on NTD eradication initiatives.
- Potential Upside: Discovery of new indications, formulation improvements, or inclusion in global health funding programs.
6. Comparison to New Antiparasitic Therapies
| Aspect | Mebendazole (Mintezol) | Newer Antiparasitics |
|---|---|---|
| Spectrum of Activity | Narrower; primarily soil-transmitted helminths | Broader (e.g., praziquantel for schistosomiasis) |
| Pharmacokinetics | Shorter half-life; single-dose efficacy | Longer half-life, less frequent dosing |
| Resistance Potential | Existing concerns; further surveillance needed | Varies; newer drugs under development |
| Cost | Low, highly affordable | Ranging from moderate to high |
| Regulatory Approvals | Widely approved, often over-the-counter | Specific indications, often prescription-only |
7. Future Opportunities & Strategic Considerations
| Opportunity Area | Strategic Insights |
|---|---|
| Drug Repurposing | Investigate efficacy against NTDs like cysticercosis, filariasis |
| Formulation Innovations | Pediatric-friendly suspensions, chewables |
| Combination Therapies | Synergistic formulations to combat resistance |
| Market Expansion | Focused efforts in endemic regions, leveraging global health subsidies |
| Regulatory Engagement | Facilitate approvals in emerging markets via OMS and WHO pathways |
8. Conclusions
Mintezol, as a generic mebendazole formulation, continues to serve an essential role in global parasitic infection management. Its market trajectory remains stable but modest, primarily driven by endemic disease control programs and public health initiatives. Competitive pressures, resistance concerns, and the advent of broader-spectrum agents challenge its long-term dominance.
However, strategic integration into global NTD eradication efforts, formulation improvements, and repositioning as a cost-effective solution in resource-limited settings will sustain its relevance. The drug's future growth hinges on global health policies, resistance management, and innovative delivery mechanisms.
Key Takeaways
- Stable Baseline: Mintezol's global revenues have plateaued but are supported by persistent demand in endemic regions.
- Competitive Pressures: Albendazole and praziquantel offer broader efficacy, challenging mebendazole's market share.
- Regulatory Environment: Favorable policies in high-endemicity countries support continued use; restrictions in high-income regions limit growth.
- Growth Opportunities: Focused efforts on drug repurposing, formulations, and integration into NTD programs can unlock new revenue streams.
- Long-term Outlook: CAGR of approximately 2% expected over the next five years, barring significant breakthroughs or global health initiatives.
FAQs
1. What are the primary therapeutic applications of Mintezol?
Mintezol (mebendazole) treats infections caused by intestinal nematodes such as roundworm, whipworm, hookworm, and pinworm. It’s also used in some cases for other parasitic infections, as approved by regional authorities.
2. How does Mintezol compete with newer antiparasitic drugs?
While less broad-spectrum than agents like albendazole and praziquantel, Mintezol remains cost-effective and is entrenched in mass drug administration programs, especially in resource-limited settings.
3. What are the main regulatory challenges for Mintezol?
Partners face restrictions or discontinuation in certain markets due to regulatory updates, safety concerns, or shifts toward integrated disease management strategies, impacting access and market expansion.
4. What is the impact of drug resistance on Mintezol's market?
Emerging reports of reduced efficacy in some regions could threaten its utility, prompting increased research into resistance management and alternative therapies.
5. Where are the significant growth opportunities for Mintezol?
Growth is anticipated mainly in endemic regions via international health programs, drug repurposing, innovative formulations, and inclusion in new combination therapies targeted at neglected tropical diseases.
References
[1] World Health Organization. “Guidelines for the treatment of soil-transmitted helminthiasis.” 2019.
More… ↓
